ijms-logo

Journal Browser

Journal Browser

Advanced Molecular Research of Gynecological Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 1592

Special Issue Editor


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, TX 78229, USA
Interests: gynecological oncology; immunotherapy; cancer stem cells; drug development; molecular diagnostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This special issue explores the latest molecular research in gynecological cancers, focusing on advancements transforming diagnosis, treatment, and patient care. It covers ovarian, cervical, uterine, and endometrial cancers, highlighting the challenges and complexities of their molecular bases. Emphasis is placed on targeted therapy and immunotherapy, examining their roles in disrupting molecular pathways and leveraging the immune system. The tumor microenvironment’s impact on cancer progression and chemoresistance is detailed. Innovative techniques like RNA sequencing, proteomics, and next-generation sequencing are showcased for uncovering new molecular targets. The issue addresses metastasis, molecular mechanisms of cancer spread, drug development, and bioinformatics, serving as a crucial resource for researchers and clinicians combating gynecological cancers.

Dr. Suryavathi Viswanadhapalli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular research
  • gynecological cancers
  • ovarian cancer
  • cervical cancer
  • uterine cancer
  • endometrial cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1493 KiB  
Article
CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix
by Gilhyang Kim, Kyung-Jun Lee, Eun Shin, Sung Taek Park, Hyeong Su Kim and Hye-Yon Cho
Int. J. Mol. Sci. 2025, 26(6), 2687; https://doi.org/10.3390/ijms26062687 - 17 Mar 2025
Cited by 1 | Viewed by 566
Abstract
CT83, a cancer-testis antigen, has emerged as a potential biomarker and therapeutic target in various cancers. This study explores its expression and role in cervical adenocarcinoma progression and prognosis. CT83 expression was analyzed in cervical cancer cell lines using quantitative PCR and Western [...] Read more.
CT83, a cancer-testis antigen, has emerged as a potential biomarker and therapeutic target in various cancers. This study explores its expression and role in cervical adenocarcinoma progression and prognosis. CT83 expression was analyzed in cervical cancer cell lines using quantitative PCR and Western blotting. Functional assays demonstrated that CT83 overexpression (OE) promotes proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in cervical cancer cells while also upregulating PD-L1 expression. Conversely, CT83 knockdown reduced these malignant phenotypes. The immunohistochemical analysis of 60 patient samples revealed CT83 expression in 84.9% of cases, with significant correlations to larger tumor size, elevated squamous cell carcinoma antigen (SCC) levels, and advanced FIGO stages (II–IV). Furthermore, intermediate-to-high CT83 expression (H-score ≥100) was associated with more aggressive disease features. These findings suggest that CT83 contributes to tumor progression and immune evasion, likely through PD-L1 modulation. As a highly expressed antigen in cervical adenocarcinoma, CT83 offers promise as a diagnostic marker and therapeutic target for improving patient outcomes. Full article
(This article belongs to the Special Issue Advanced Molecular Research of Gynecological Cancer)
Show Figures

Figure 1

Review

Jump to: Research

26 pages, 1922 KiB  
Review
Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target
by Emily J. Aller, Hareesh B. Nair, Ratna K. Vadlamudi and Suryavathi Viswanadhapalli
Int. J. Mol. Sci. 2025, 26(10), 4809; https://doi.org/10.3390/ijms26104809 - 17 May 2025
Viewed by 518
Abstract
Midkine (MDK) is a multifunctional protein that is secreted into the extracellular space. It functions as a cytokine or growth factor, modulating a variety of signaling pathways implicated in angiogenesis, antitumor immunity, metastasis, and therapy resistance. MDK overexpression has been documented in a [...] Read more.
Midkine (MDK) is a multifunctional protein that is secreted into the extracellular space. It functions as a cytokine or growth factor, modulating a variety of signaling pathways implicated in angiogenesis, antitumor immunity, metastasis, and therapy resistance. MDK overexpression has been documented in a variety of cancers, including those that affect women. MDK mediates its effects through activation of key signaling pathways such as MAPK/ERK, PI3K/AKT, and STAT3, which are pivotal for cell cycle progression, survival, and maintenance of stemness. Obesity and estrogen signaling, a known critical driver of women’s cancer, further elevate the levels of MDK. MDK’s effects are mediated by a variety of membrane receptors, such as integrins, protein tyrosine phosphatase ζ (PTPζ), anaplastic lymphoma kinase (ALK), and neurogenic locus notch homolog protein 2 (Notch2). Recently published studies have indicated that MDK is a potential therapeutic target and a biomarker for the progression of women’s cancer. In this review, we have provided a concise summary of the most recent papers that have examined the potential biomarker and therapeutic utility of MDK signaling in women’s cancer. Full article
(This article belongs to the Special Issue Advanced Molecular Research of Gynecological Cancer)
Show Figures

Figure 1

Back to TopTop